My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

42.93 -1.08 (-2.45%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 13, 2025

From Scholar Rock

Via Business Wire

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗

December 03, 2025

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

Via The Motley Fool

Topics Regulatory Compliance

Scholar Rock to Present at Upcoming Investor Conferences

November 18, 2025

From Scholar Rock

Via Business Wire

Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗

November 14, 2025

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Via Chartmill

Why Is Scholar Rock Holding Stock Climbing Today? ↗

November 14, 2025

Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.

Via Benzinga

Why Did Scholar Rock Soar 26% Today? ↗

November 14, 2025

The company is planning to reapply for approval of a muscle atrophy therapy in the coming year.

Via Stocktwits

Topics Earnings

Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher ↗

November 14, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 14, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.

Via Chartmill

Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday ↗

November 14, 2025

Via Benzinga

Scholar Rock Holding Corp (NASDAQ:SRRK) Posts Wider-Than-Expected Q3 2025 Loss Amid Key Launch Preparations ↗

November 14, 2025

Scholar Rock invests heavily in its lead drug apitegromab, targeting a 2026 launch for spinal muscular atrophy despite a wider Q3 2025 loss.

Via Chartmill

Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 14, 2025

From Scholar Rock

Via Business Wire

Earnings Scheduled For November 14, 2025 ↗

November 14, 2025

Via Benzinga

Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks ↗

November 13, 2025

Lucid, Avis, Hims & Hers Health and Upstart are some of the most heavily shorted stocks right now. Here's a look at the top ten.

Via Benzinga

What to Expect from Scholar Rock Holding's Earnings ↗

November 13, 2025

Via Benzinga

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 12, 2025

From Scholar Rock

Via Business Wire

3 Beaten-Down Stocks With Rebound Potential This Earnings Season ↗

November 12, 2025

Via MarketBeat

Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

November 04, 2025

From Scholar Rock

Via Business Wire

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025

October 23, 2025

From Scholar Rock

Via Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 17, 2025

From Scholar Rock

Via Business Wire

Alpha Buying: 3 Stocks With Sky-High Insider Confidence ↗

October 14, 2025

Via Benzinga

Why Scholar Rock Stock Got Socked on Monday ↗

October 13, 2025

The biotech suffered a regulatory setback last month, and this new development might be another blow to its prospects.

Via The Motley Fool

Topics Earnings

Why Is Scholar Rock Stock Trading Lower On Monday? ↗

October 13, 2025

Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial.

Via Benzinga

Why Are Regeneron And Scholar Rock Shares Falling On Monday? ↗

October 13, 2025

Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk.

Via Stocktwits

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 13, 2025

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

October 13, 2025

Via Chartmill

Fastenal Posts Downbeat Earnings, Joins Vince Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

October 13, 2025

Via Benzinga

Why Scholar Rock Stock Raced 6% Higher Today ↗

October 09, 2025

A pundit at an influential U.S. bank is quite bullish on the company's future.

Via The Motley Fool

This Oracle Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗

October 09, 2025

Via Benzinga

Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday ↗

September 26, 2025

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA...

Via Benzinga

Topics Stocks

Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection ↗

September 23, 2025

FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germany as the launch market.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.